ClinicalTrials.gg
RecruitingNCT06723886OPODIABEUpdated Dec 11, 2024

Antidiabetic Effect of Olive Pomace Oil

An interventional study of Experimental arm: Olive pomace oil and High-oleic acid sunflower oil in Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) and Prediabetic State, sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición. Recruiting at 1 site in Spain. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.

Planned enrollment
351st of 383
50 · median 484
Started
2025
with 17 others
No phase
77 of 429
17 open now
Primary completion
2026-03
later than 13 of 54 live
Registered
384th of 429
by date

Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 351st largest by planned enrollment of the 383 interventional ones that give a count, is one of 18 that started in 2025, is one of 77 with no phase, reaches primary completion later than 13 of the 54 other live ones, and was the 384th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, or all of them as a file.
02

Study summary

This clinical trial aims at assessing whether consumption of olive pomace oil in the diet may benefit persons with type 2 diabetes mellitus or persons at risk of developing the disease (prediabetic persons).

The main questions the study aims to answer are:

  • May olive pomace oil prevent a high increase of blood glucose levels when consumed in a meal together with carbohydrates in diabetic/prediabetic patients?
  • May olive pomace oil decrease fasting blood glucose levels of diabetic/prediabetic patients after consuming it daily?
  • May daily consumption of olive pomace oil improve glucose homeostasis and other alterations like elevated blood lipids or inflammation, which also affect persons with diabetes or prediabetes?

Researchers will compare the effect of consuming olive pomace oil to the effects of a comparison oil (high-oleic acid sunflower oil).

Participants will:

In different days, they will consume white bread alone or the oils (olive pomace oil, high-oleic acid sunflower oil or extra virgin olive oil) spread on white bread and blood will be collected at different times during 2 h. This study to observe the increase of blood glucose after a carbohydrate-rich breakfast will be part of the so-called "postprandial" study, and will be conducted during 3 weeks, during which participants will consume corn oil on a daily basis.

Participants will also take part in the "chronic" study, that will last 22 weeks in total. During this study, they will firstly "wash" the effects of the oil they normally consume in their diets by consuming corn oil during 3 weeks. It is during these weeks when they will attend the Human Nutrition Unit (HNU) of ICTAN to carry on the "postprandial" study described in the previous paragraph.

After the initial 3 weeks, participants will consume olive pomace oil as the only oil in their diets during 8 weeks, "wash" its effects again by consuming corn oil during 3 weeks and then change to consume the other oil (high-oleic acid sunflower oil) during 8 weeks.

During the chronic study, they will visit the clinic once every 4 weeks for checkups and tests. They will refrain from eating other oils or specific fat-rich foods. Participants will also attend our phone calls to ask them what they ate the day before on different weeks during the study, and wear an accelerometer during 1 week to record their physical activity. They will keep a diary of the doses of insulin/metformin used and the blood glucose levels they measured at home.

Read the detailed description

This trial comprises 2 studies in parallel, a postprandial study and a chronic intervention.

In the postprandial study, participants will attend the Human Nutrition Unit (HNU) of ICTAN in different days. During these visits, they will consume white bread (50 g) alone or with 10 g of extra virgin olive oil (EVOO), olive pomace oil (OPO) or high-oleic acid sunflower oil (HOSO). A nurse will insert a catheter in the non-prevailing arm and collect fasting blood (0 h) and blood samples 1 and 2 h after consuming the bread/oil to measure the postprandial glycemic/insulinemic response, as well as incretins (GLP-1, GIP). Blood lipids will also be determined. These visits will be carried out during the 3-week run-in period prior to the chronic intervention, when the EVOO and control (white bread) tests will be carried out (weeks 1 and 2, respectively). Then, coinciding with the first day of the chronic intervention, participants will consume either OPO or HOSO as corresponding to the randomized allocation to each oil. The other postprandial test will be carried out at the beginning of the second intervention after crossover and wash-out, thus avoiding additional visits and discomfort to the participants.

The chronic study is a crossover, randomized, blind, clinical trial. After a 3-week run-in during which participants will consume corn oil as the only dietary oil, they will be randomly allocated to one of each intervention arms, OPO or HOSO, each lasting 8 weeks. Then, a 3-week wash-out period with corn oil will follow before changing to consuming the other oil.

During the study, participants should avoid other oils and fats such as olives, sunflower seeds, butter, margarine, nuts or avocados.

During the chronic intervention, participants will visit the HNU at the beginning (week 1), middle (week 4) and at the end (week 8) of each intervention arm. A nurse will collect a fasting blood sample and measure blood pressure. An analysis of body weight and body composition (anthropometric and bioimpedance measurements) will be performed. Participants should maintain their habitual diet and exercise level throughout the study; diet will be monitored by periodic 24-h recall questionnaires (a trained member of the team will phone participants on 3 different days (including a festive one) before each visit to the HNU to enquire what they ate the previous day). In addition, a physical activity questionnaire will be completed at the beginning of the study and, on each intervention arm, participants will carry during 7 days an accelerometer to monitor real physical activity.

Biochemical, hormonal and inflammatory markers will be measured in blood samples to assess the potential effect of olive pomace oil on different outcomes of relevance in the management of blood glucose in diabetic/prediabetic persons, including glucose homeostasis, insulin resistance, blood lipid levels, liver function, different hormones, incretins, adipokines, pro- and anti-inflammatory cytokines, on integrity of the intestinal barrier.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
  • Prediabetic State
  • Diabetes
  • Diabetes Mellitus

Keywords

  • Olive pomace oil
  • Diabetes
  • Prediabetes
  • Antidiabetic effect
  • Postprandial study
  • Chronic intervention
  • High-oleic acid sunflower oil
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting blood glucose between 100-126 mg/dL and/or
  • (HbA1c) between 5.7-6.4% and/or
  • Diabetic persons with Fasting blood glucose >126 mg/dL and/or
  • Diabetic persons with Glycated haemoglobin (HbA1c) > 6.4%

Exclusion criteria

Exclusion Criteria:

  • Kidney or liver diseases
  • Gastrointestinal diseases (irritable bowel syndrome, Crohn disease, chronic bowel inflammation)
  • Food allergies/intolerances
  • Vegetarians/vegans
  • Smoking
  • Pregnant or lactating women
  • On prescription drugs other than for hypertension/thyroid/dyslipidemia/glucose control, or changes in dosage in the last 3 months
  • Consumption of vitamins, dietary supplements or nutraceuticals
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Olive pomace oil

    Consumption of olive pomace oil as the only dietary fat.

    Dietary Supplement: Experimental arm: Olive pomace oil

  • Active comparator
    High-sunflower olive oil

    Consumption of high-oleic acid sunflower oil as the only dietary fat.

    Dietary Supplement: High-oleic acid sunflower oil

Interventions

  • Dietary supplementExperimental arm: Olive pomace oil

    Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.

  • Dietary supplementHigh-oleic acid sunflower oil

    Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.

06

What researchers measure

Primary outcomes

  1. Fasting blood glucose

    Change of fasting blood glucose levels at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  2. Postprandial blood glucose response

    Change of postprandial blood glucose levels after consuming white bread with oil in comparison with white bread only. Blood will be collected at 0 h and 1 and 2 h after consuming the bread alone or with the corresponding oil. Olive pomace oil (active comparator) and high-oleic acid sunflower oil (active comparator) will be tested. Only in this postprandial study extra virgin olive oil will also be tested as a positive control (at the beginning of the run-in), along with white bread only (at week 2 of the run-in). Test/comparator oils will be assessed at the beginning of each arm, week 1 of each intervention arm (corresponding to weeks 4 and 14 of the study).

    Time frame: From enrollment until week 14 of the study

Secondary outcomes

  1. Insulin levels

    Change in fasting blood insulin levels at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  2. Insulin resistance

    Change in homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  3. Insulin sensitivity

    Change in quantitative insulin levels sensitivity check index (QUICKI) at the end of the chronic intervention. Higher score in QUICKI means a better outcome compared to initial values.

    Time frame: From enrollment to the end of each treatment at 8 weeks

  4. Glycated hemoglobin

    Change in blood levels of glycated hemoglobin (HbA1c) at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  5. Beta-cell function

    Change in homeostasis model assessment (HOMA) of beta-cell function (HOMA-B) at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  6. Postprandial insulin response

    Change of postprandial blood insulin levels after consuming white bread with oil in comparison with white bread only. Blood will be collected at 0 h and 1 and 2 h after consuming the bread alone or with the corresponding oil. Olive pomace oil (active comparator) and high-oleic acid sunflower oil (active comparator) will be tested. Only in this postprandial study extra virgin olive oil will also be tested as a positive control (at the beginning of the run-in), along with white bread only (at week 2 of the run-in). Test/comparator oils will be assessed at the beginning of each arm, week 1 of each intervention arm (corresponding to weeks 4 and 14 of the study).

    Time frame: From enrollment to week 14 of the study

  7. Postprandial incretins

    Change of postprandial levels of GLP-1 and GIP after consuming white bread with oil in comparison with white bread only. Blood will be collected at 0 h and 1 and 2 h after consuming the bread alone or with the corresponding oil. Olive pomace oil (active comparator) and high-oleic acid sunflower oil (active comparator) will be tested. Only in this postprandial study extra virgin olive oil will also be tested as a positive control (at the beginning of the run-in), along with white bread only (at week 2 of the run-in). Test/comparator oils will be assessed at the beginning of each arm, week 1 of each intervention arm (corresponding to weeks 4 and 14 of the study).

    Time frame: From enrollment to week 14 of the study

  8. Postprandial blood lipids

    Change of postprandial blood lipid levels after consuming white bread with oil in comparison with white bread only. Blood will be collected at 0 h and 1 and 2 h after consuming the bread alone or with the corresponding oil. Olive pomace oil (active comparator) and high-oleic acid sunflower oil (active comparator) will be tested. Only in this postprandial study extra virgin olive oil will also be tested as a positive control (at the beginning of the run-in), along with white bread only (at week 2 of the run-in). Test/comparator oils will be assessed at the beginning of each arm, week 1 of each intervention arm (corresponding to weeks 4 and 14 of the study).

    Time frame: From enrollment to week 14 of the study

Other outcomes

  1. Blood lipids

    Change in serum levels of total cholesterol or LDL-cholesterol or HDL-cholesterol or triglycerides or apolipoprotein A1 or apolipoprotein B at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  2. Inflammatory cytokines

    Change in the levels of C-reactive protein (CRP), or pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-a), or interferon gamma (IFN-g), or interleukin (IL)-1beta (IL-1b), or IL-2, or IL-5, or IL-6, or IL-7, or IL-8, or IL-13)) or anti-inflammatory cytokines IL-4 or IL-10 at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  3. Liver function

    No changes in serum levels of alanine transferase (ALAT), or aspartate transferase (ASAT) or gamma-glutamyl transferase (GGT) at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  4. Hormones, incretins and adipokines levels

    Changes in serum levels of C peptide or glucagon or fibroblast growth factor 21 (FGF21) or glucagon inhibitory peptide (GIP) or glucagon-like peptide type 1 (GLP-1) or ghrelin or leptin or resistin or plasminogen activator inhibitor type 1 (PAI-1) or visfatin or adiponectin or adipsin or dipeptidyl peptidase IV (DPP IV) at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

  5. Intestinal barrier function

    Changes in blood levels of lipopolysaccharide (LPS) or zonulin at the end of the chronic intervention

    Time frame: From enrollment to the end of each treatment at 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Institute of Food Science, Technology and Nutrition (ICTAN-CSIC)
    Madrid, 28040, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Interesting researchers may contact the principal investigator

Supporting information: Study protocol, Informed consent form

Time frame: After completion of the study and publication of results

Access criteria: Justified request to the principal investigator

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Mar 2026, 14 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 14 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartEst.
Jan 15, 2025
Primary completionEst.
Mar 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06723886
Lead sponsor
Instituto de Ciencia y Tecnología de Alimentos y Nutrición
Collaborators
ICTAN-CSIC - Madrid - Spain
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Jan 15, 2025 (estimated)
Primary completion
Mar 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Dec 11, 2024

Study contacts

Laura Bravo, Professor
Contact
lbravo@ictan.csic.es
+34 91 5492300 ext. 436350
Beatriz Sarria, Dr
Contact
beasarria@ictan.csic.es
+34 91 5492300 ext. 436342
Laura Bravo, Professor
principal investigator · ICTAN-CSIC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion